Enable Injections Names Matthew Huddleston as Chief Commercial Officer
22 Mayo 2024 - 6:30AM
Enable Injections, Inc. (“Enable”), a
healthcare innovation company developing and manufacturing
the enFuse® wearable drug delivery platform today announced
the appointment of Matthew Huddleston, previously Executive Vice
President and Chief Technology Officer at Enable, to Chief
Commercial Officer.
Mr. Huddleston will be responsible for leading
Enable’s current marketing and business development operations and
expanding the Company’s commercial infrastructure as it works with
its growing list of pharmaceutical partners to prepare for joint
commercial launch of their therapies in combination with enFuse.
The first enFuse combination product received U.S. Food and Drug
Administration approval in 2023.
enFuse is an innovative, wearable drug delivery
platform designed to deliver large volumes of medications
subcutaneously, in which patients receive their needed treatment in
a simple injection under the skin, instead of intravenously. enFuse
is designed to overcome both IV infusion and other subcutaneous
administration method shortcomings through fast, simple, and
convenient delivery, benefiting patients, providers, as well as
payers, with the ability for patient self-administration.
“Since joining the company in 2012, Matt has been
an invaluable asset to the Enable team and to our success. His
knowledge of the medical device industry and expertise in
engineering led him to be a significant contributor to the core
elements of our wearable enFuse technology, while simultaneously
playing an instrumental role in our business development efforts,
including brokering our six ongoing pharmaceutical partnerships,”
said Mike Hooven, Chairman and CEO of Enable Injections. “Matt will
continue to be an influential leader in his new role as Chief
Commercial Officer as we prepare to launch more commercial
products.”
Mr. Huddleston is an accomplished medical device
professional with more than 30 years of experience. He has several
issued and pending patents, including soft tissue and
cardiovascular fixation devices and delivery instruments,
histologic automated embedding systems, laparoscopic visualization
devices, and automatic injection devices. He is a professional
engineer and a licensed patent agent. Mr. Huddleston holds a
Bachelor of Science in Mechanical Engineering from Purdue
University and a Master of Science in Biomedical Engineering from
The Ohio State University.
“Throughout my time at Enable, I’ve been focused on
developing an innovative wearable technology that will benefit
patients and our pharmaceutical partners, creating a drug delivery
alternative that is simple, easy to use, and enhances the treatment
experience,” said Matthew Huddleston, Chief Commercial Officer of
Enable Injections. “I’ve held many different positions over the
years, and it’s been an honor to be part of the growth of this
company, from inception to our first approved product. I’m looking
forward to further developing Enable and our team as I step into
this new role and focus on our commercialization path.”
About Enable
InjectionsCincinnati-based Enable Injections is a global
healthcare innovation company committed to improving the patient
treatment experience through the development and manufacturing of
enFuse®. enFuse is an innovative wearable drug delivery platform
that is designed to deliver large volumes of pharmaceutical and
biologic therapeutics via subcutaneous administration, with the aim
of improving convenience, supporting superior outcomes, and
advancing healthcare system economics. For more information about
the Company’s approved enFuse combination production, visit
https://enableinjections.com/our-products.
Media Contact:Sheryl Seapysseapy@realchemistry.com
(949) 903-4750